Overview
Retatrutide is a next-generation triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. In clinical trials it demonstrated superior weight loss outcomes compared to dual agonists, with Phase 2 data showing up to 24% reduction in body weight over 48 weeks. Its glucagon receptor activity provides additional energy expenditure benefits beyond GLP-1 alone.
Mechanism of action
Retatrutide activates GLP-1 receptors to suppress appetite and slow gastric emptying, GIP receptors to enhance insulin secretion and fat metabolism, and glucagon receptors to increase hepatic glucose output and thermogenesis. This multi-receptor engagement produces synergistic metabolic effects that exceed single or dual agonists in preclinical and early clinical data.
Selected literature
- [01]
Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial
Jastreboff A.M. et al. · New England Journal of Medicine · 2023
Retatrutide produced up to 24.2% mean weight reduction at 48 weeks, the highest reported for any obesity pharmacotherapy to date.
- [02]
Glucagon receptor agonism in metabolic disease
Day J.W. et al. · Nature Chemical Biology · 2009
Combined GLP-1/glucagon receptor activation produced greater fat loss and metabolic improvement than GLP-1 alone in preclinical models.
- [03]
GIP and GLP-1 receptor co-agonism for weight management
Finan B. et al. · Science Translational Medicine · 2013
Dual incretin receptor agonism demonstrated synergistic reductions in body weight and improved insulin sensitivity versus monotherapy.
The information on this page is summarized from the published research literature and is provided for reference and educational purposes only. It is not medical advice and should not be used to guide treatment decisions. Our peptides are sold for in-vitro research and laboratory use only.